List of partners

The following companies and organisations have confirmed their participation in the 36th ECNP Congress.
The content of the below mentioned websites, sessions or exhibition stands does not necessarily reflect the opinion of ECNP, nor does it engage its responsibility. The exhibition floor plan can be found here.

In alphabetical order:

ALBA Network
Exhibition stand in Barcelona, number 19
Virtual exhibition

The ALBA Network was created to promote equity and diversity in the brain sciences. The goals of ALBA are to recognize implicit bias and discrimination, and to provide better visibility and professional development opportunities to scientists from underrepresented groups in brain research. This is achieved by highlighting diverse scientist profiles through a series of interviews; organizing webinars discussing EDI issues, awards, mentoring sessions and networking events; and providing a platform to disseminate data and best practices towards creating a more inclusive brain research community. To discover all our activities and become a member, visit


   ALBA Network

Angelini Pharma
Industry Product Theatre IPT.01

Angelini Pharma is an international pharmaceutical company, part of the Italian privately-owned Angelini Industries. Angelini Pharma is committed to helping patients in the therapeutics areas of Brain Health, Rare Diseases and Consumer Healthcare. Angelini Pharma operates directly in 25 countries employing almost 3.000 people and commercializes its products in more than 50 countries through strategic alliances with leading international pharmaceutical groups.


  Angelini Pharma

Industry Satellite Symposium ISS.02
Exhibition stand in Barcelona, number 4
Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.



Boehringer Ingelheim
Industry Satellite Symposium ISS.03
Industry Satellite Symposium ISS.06
Exhibition stand in Barcelona, number 2
Virtual exhibition

Boehringer Ingelheim Mental Health At Boehringer Ingelheim Mental Health, we are redefining mental health to enable people to thrive. We link behavior to the underlying neurobiology to develop targeted therapies that can ease the burden of these conditions, not just the symptoms. By combining traditional treatment with new and innovative approaches and technologies, we will enable those with mental health conditions to create more meaningful connections to their lives, loved ones and society.


   Boehringer Ingelheim

Exhibition stand in Barcelona, number 22
Virtual exhibition

EUFAMI was founded in 1992 after a congress, which took place in 1990 in De Haan, Belgium, where carers from all over Europe shared their experiences of helplessness and frustration when living with severe mental illness. They resolved to work together to help both themselves and the people they cared for. EUFAMI is a democratic organisation, registered in Belgium as an international non-profit organisation. We have an ongoing commitment to improving care and welfare for people affected by mental illness. We also enable our member organisations to act jointly at a European Level, combining their efforts and sharing experience.



European Brain Council (EBC)
Exhibition stand in Barcelona, number 18
Virtual exhibition

The European Brain Council (EBC) is a network of key players in the “Brain Area”, with a membership encompassing scientific societies, patient organisations, professional societies and industry partners. A non-profit organisation based in Brussels, its main mission is to promote brain research with the ultimate goal of improving the lives of the estimated 179 million Europeans living with brain conditions. With the aim to speak with one voice, EBC stands as the platform to foster cooperation between its member organisations and other stakeholders, consistently promoting dialogue between scientists, industry and society.



European Psychiatric Association (EPA)
Exhibition stand in Barcelona, number 23
Virtual exhibition

With activities that address the interests of psychiatrists in academia, research and practice throughout all stages of career evolution, the European Psychiatric Association is the main association representing psychiatry in Europe. Being a part of the EPA means joining a community of practitioners, scientists, and professionals who are committed to the improvement of care for the mentally ill and to the development of professional excellence. With the help of mental health care partners across all related disciplines, the EPA’s leaders and members also strive to enact positive policy change at local, national and international levels.


   European Psychiatric Association (EPA)

Exhibition stand in Barcelona, number 21
Virtual exhibition

Global Alliance of Mental Illness Advocacy Networks-Europe (GAMIAN-Europe), is a not-for-profit patient-driven pan-European organisation, representing and advocating the interests and rights of persons affected by mental ill health. Its principal activities relate to advocacy, information, awareness-raising, education, partnership and capacity building. Overarching themes in our work relate to anti-stigma and discrimination and patients’ rights.


Gedeon Richter Plc & RECORDATI S.p.A
Industry Mini Session IMS.03
Exhibition stand in Barcelona, number 5

Headquartered in Hungary, Gedeon Richter is an innovation-driven speciality pharmaceutical company, boasting the biggest pharmaceutical research centre in CEU. One of its latest achievements is the original antipsychotic compound, cariprazine, already marketed in the US for for Schizophrenia, BD and aMDD treatment and in the majority of the EU countries for the treatment of schizophrenia in adult patients.

Recordati is an international pharmaceutical group, listed on the Italian Stock Exchange, dedicated to the research, development and marketing of pharmaceuticals products. Recordati is committed to the research and development of new specialities in cardiovascular, urological and psychiatric areas with a focus on treatments for rare diseases.






GH Research
Industry Interactive Discussion IID.01

GH Research is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The initial focus is on developing a novel and proprietary 5- Methoxy-N,N-Dimethyltryptamine, or 5-MeO-DMT, therapy for the treatment of patients with Treatment Resistant Depression. The lead product candidate, GH001, is formulated for 5-MeO-DMT administration via a proprietary inhalation approach.



Janssen Pharmaceutica NV
Industry Satellite Symposium ISS.07
Exhibition stand in Barcelona, number 1

At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.


  Janssen Pharmaceutica NV 

Karuna Therapeutics
Industry Satellite Symposium ISS.11

Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. We pride ourselves on our expertise in neuroscience and inventive thinking around drug discovery and development. We have worked to advance a pipeline of novel medicines with the goal of making a difference in the lives of those affected by these complex conditions.


   Karuna Therapeutics

Laboratorios Farmacéuticos ROVI
Industry Satellite Symposium ISS.05
Exhibition stand in Barcelona, number 3

ROVI is a European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The company has subsidiaries in Portugal, Germany, the United Kingdom, Italy France and Poland, as well as presence in more than 50 countries worldwide. ROVI has a diversified portfolio in therapeutic areas such as, Psychiatry, Cardiology, Hematology and Urology among others and continues to develop a leading-edge line of research in the field of prolonged drug release.



Exhibition stand in Barcelona, number 6

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases.



Neuroscience-based Nomenclature (NbN)
Exhibition stand in Barcelona, number 20 
Virtual exhibition

NbN is a product of an unprecedented, unique collaboration of four colleges of neuropsychopharmacology: ECNP, CINP, ACNP, AsCNP, and IUPHAR. The proposal was to move from the indication-based to a pharmacologically-driven nomenclature. By doing so, NbN enriches our vocabulary; using pharmacology in prescribing provides us with 64 groups of medications in our prescribing tool box. Our current, disease-based, nomenclature uses the terms "antidepressants", "antipsychotics" (including "second generation" antipsychotics), "mood stabilizers", "anxiolytics" etc., which does not do justice to the wealth of neuroscience knowledge that has been accumulated in the past 60 years.


  Neuroscience based Nomenclature (NbN) 

Otsuka Pharmaceutical Europe Ltd.
Industry Satellite Symposium ISS.04

At Otsuka Europe we all share the same values and are dedicated to a common purpose: Otsuka-people creating new products for better health worldwide. Otsuka-people channel their passion and commitment into aiming to improve the health of our patients. Together we are focusing on some of the world’s unresolved health issues and creating solutions and opportunities for some of the most challenging conditions of the body and mind.



Sunovion Pharmaceuticals Inc. and Otsuka Pharmaceutical Development & Commercialization Inc.
Industry Satellite Symposium ISS.09

Two teams with medical and scientific expertise working together to investigate innovative neuropsychiatric treatments in schizophrenia and other serious mental health conditions.





Takeda Pharmaceuticals
Industry Interactive Discussion IID.02

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI), with expertise in immune and inflammatory diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.


  Shire Denmark - Takeda group

Teva Pharmaceuticals
Exhibition stand in Barcelona, number 10

Teva Pharmaceuticals has been developing and producing medicines to help improve people’s lives for more than a century. We are committed to being a global leader in generic and specialty medicines with a portfolio of 3,600 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day. They are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products.



Industry Satellite Symposium ISS.08

Viatris, a global healthcare company, has a strong heritage in mental health with iconic, globally recognized brands (e.g., Zoloft, Effexor, Xanax, Leponex, Zeldox). Our portfolio meets the needs of people living with mental health conditions (from anxiety, depression to schizophrenia and treatment resistant schizophrenia). We operate globally in more than 165 countries. At Viatris, we understand the challenges associated with mental health conditions. We work alongside all stakeholders to raise awareness, bridge knowledge gaps, enhance access to help patients, their families, caregivers, and healthcare professionals overcome the burden of illness. We are committed to helping create healthier communities worldwide.



Wisepress Medical Bookshop
Exhibition stand in Barcelona, number 17, Europe’s leading conference bookseller, attend around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of this conference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter @WisepressBooks.